Visual Function In Ethambutol Induced Optic Neuropathy At a Tertiary Eye Centre: A Retrospective Study
Open Access
- 30 April 2025
- journal article
- Published by Birat Medical College and Teaching Hospital in Birat Journal of Health Sciences
- Vol. 10 (1) , 82-88
Abstract
Introduction: Ethambutol is an important and widely used drug in the treatment of both tubercular and non-tubercular mycobacterial disease as it is the least toxic of the first line antituberculosis drugs. The main disadvantage of this drug is its associated ocular toxicity, manifesting as optic neuropathy. Objectives: To describe the demography, risk factors and visual function in Ethambutol induced Optic Neuropathy (EON) among patients presenting at a tertiary eye centre in Nepal. Methodology: This retrospective study was conducted at B.P. Koirala Lions Centre for Ophthalmic Studies, Institute of Medicine, where all consecutive patients with ethambutol induced optic neuropathy presenting from 1st April 2022 to 30th March 2024 were recorded. Parameters recorded were patient demographics (age, gender and ethnicity), presenting complaints, duration and dosages of ethambutol, body weight, visual acuity, colour vision, contrast sensitivity and visual field. Results: There were 14 patients (28 eyes) of ethambutol induced optic neuropathy. The mean age of patients taking ethambutol was 50.64± 15.8 years with mean daily dose of 18.27 ± 2.29 mg/kg per day. Bilateral ocular involvement was seen with visual acuity ranging from CFCF to 20/60 in one or both eyes. The most common color vision defect was nonspecific defect seen in six patients. The most common visual field defect was centrocecal scotoma in six cases. Mean contrast sensitivity was 1.50±0.32 log units. Thinning of the RNFL and GCC were seen in all cases of EON and the thinning correlated with the severity of visual loss. Conclusions: EON was seen at a mean dose of 18.27mg/kg and mean duration of 7.25 months with moderate to severe visual loss and decrease in contrast sensitivity and visual field defects. Average RNFL thinning and GCC thinning correlated with the severity of visual loss seen in EON subjects. Awareness and early diagnosis can help reduce the unnecessary blindness due to this condition in the susceptible group.Keywords
This publication has 28 references indexed in Scilit:
- Nfe2l3 promotes neuroprotection and long-distance axon regeneration after injury in vivoExperimental Neurology, 2024
- Longitudinal analysis of retinal nerve fiber layer and ganglion cell–inner plexiform layer thickness in ethambutol-induced optic neuropathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2015
- Toxic optic neuropathies: an updated reviewActa Ophthalmologica, 2014
- Visual Function in Patients on Ethambutol Therapy for TuberculosisJournal of Ocular Pharmacology and Therapeutics, 2011
- Incidence and Clinical Features of Ethambutol-Induced Optic Neuropathy in KoreaJournal of Neuro-Ophthalmology, 2008
- The Role of Copper on Ethambutol’s Antimicrobial Action and Implications for Ethambutol-induced Optic NeuropathyDiagnostic Microbiology and Infectious Disease, 1998
- Visual Function in Recovered Ethambutol Optic NeuropathyJournal of Ocular Pharmacology and Therapeutics, 1995
- Ocular toxicity following ethambutol in standard dosageRespiratory Medicine, 1986
- Ocular Toxicity from EthambutolAmerican Journal of Ophthalmology, 1974
- THE OCULAR TOXICITY OF ETHAMBUTOL AND ITS RELATION TO DOSE*Annals of the New York Academy of Sciences, 1966